U

United Therapeutics Corporation

Biotech company develops PAH therapies

Executive Director - Global Safety Strategy & Benefit Risk Management

Full-TimeUpdated on 10/23/2026
$275k - $375k/yr
Expert
MD
Remote in USA+1 moreMore locations: Research Triangle Park, Durham, NC, USA
RemoteUnited States (remote): Remote option is limited to the continental United States.
Biology & Biotech

About the job

Requirements
  • An MD is required.
  • At least 10 years of experience leading a safety risk management organization in pharma or biopharma is required.
  • At least 3 years of experience managing other MDs or sub-investigators is required.
  • At least 5 years of clinical trial support experience, as a principal investigator, sub-investigator, or development team member, is required.
  • At least 3 years of experience working in a matrix team environment, including supporting other team members when required, is required.
  • Ability to promote collegiality and teamwork among peers in a matrix environment is required.
  • Proficiency with Microsoft Office, including Word, Excel, Outlook, and PowerPoint, is required.
  • Data analytics experience with tools such as Excel, patient listing reviews, dashboards, Spotfire, or QlikView is required.
  • Ability to search a wide range of literature and clinical sources to collect evidence-based data and synthesize sound clinical conclusions is required.
  • Excellent oral and written communication skills to support responses to health authority requests are required.
  • Interpersonal and time management skills to ensure compliance with firm timelines are required.
  • Ability to think strategically, develop independent and reasoned solutions to safety issues, and minimize risk to patients within a program or commercial therapy is required.
  • Ability to influence internal and external stakeholders, reach consensus, and meet regulatory, safety, and business objectives is required.
  • Demonstrated problem-solving skills that enact change and drive continuous improvement are required.
  • Ability to be flexible, adaptable, and open-minded in a constantly changing environment is required.
  • Ability to build and manage cross-functional relationships by motivating and inspiring others is required.
  • Ability to work proactively and independently under minimal direction is required.
Responsibilities
  • Develop and execute the global safety strategy across investigational and commercial products throughout the product lifecycle for the pulmonary portfolio.
  • Establish scientific frameworks for benefit-risk assessment, safety surveillance, and risk minimization strategies.
  • Partner with executive leadership to integrate patient safety into corporate development, regulatory, and commercialization strategies.
  • Anticipate emerging scientific, regulatory, and business risks and develop mitigation strategies.
  • Provide executive oversight of benefit-risk assessments supporting global regulatory submissions, lifecycle management, safety governance committees, and health authority interactions.
  • Lead enterprise discussions about evolving product safety profiles and recommendations affecting development strategy and marketed products.
  • Ensure consistent application of benefit-risk principles across therapeutic areas and product platforms.
  • Chair or participate in senior governance committees supporting product safety decisions.
  • Provide scientific leadership for signal detection and evaluation, aggregate safety assessments, literature surveillance, epidemiology, and safety science activities.
  • Oversee development of safety strategies supporting Risk Management Plans, Risk Evaluation and Mitigation Strategies, post-authorization safety studies, post-authorization efficacy studies, and post-authorization safety commitments.
  • Ensure safety decisions are evidence-based and scientifically defensible.
  • Guide complex medical evaluations requiring expert clinical judgment.
  • Establish governance frameworks supporting consistent safety decision-making across the organization.
  • Provide executive oversight for safety review committees, including PSMT, PSRC, MARC, PLRC, DMC, and other governance forums.
  • Ensure alignment among Global Patient Safety, Clinical Development, Regulatory Affairs, Medical Affairs, Commercial, Manufacturing, Quality, and Business Development.
  • Drive enterprise inspection readiness for safety governance processes.
  • Lead pharmacovigilance strategy supporting global regulatory submissions, inspections, product approvals, and lifecycle management.
  • Represent Global Patient Safety during executive meetings with regulatory agencies.
  • Interpret evolving FDA, EMA, MHRA, PMDA, Health Canada, and international pharmacovigilance requirements.
  • Guide organizational implementation of new regulatory expectations affecting benefit-risk evaluation.
  • Provide strategic leadership and direct oversight of Brand Safety Leads and Medical Safety Physicians aligned to each product.
  • Maintain executive oversight of products without dedicated Brand Safety Leads to ensure consistent scientific review and regulatory compliance.
  • Establish performance expectations and scientific standards across the Brand Safety organization.
  • Mentor physicians and safety leaders and develop future organizational capability.
  • Serve as the senior safety representative supporting Product Development Teams.
  • Influence executive decisions regarding clinical development strategy, protocol design, safety monitoring, regulatory filings, due diligence, licensing opportunities, and lifecycle management.
  • Collaborate with Global Patient Safety Operations to align operational execution with scientific strategy and regulatory expectations.
  • Partner with Alliance Management to ensure consistent safety oversight across affiliates, licensing partners, and commercial collaborators.
  • Maintain executive accountability for inspection readiness related to safety science, benefit-risk management, and safety governance.
  • Lead responses to complex regulatory inspections and significant safety findings.
  • Oversee corrective and preventive actions related to scientific or regulatory observations.
  • Ensure safety activities comply with global pharmacovigilance regulations, ICH guidelines, GVP modules, FDA requirements, and international standards.
  • Drive pharmacovigilance innovation through AI, advanced analytics, automation, and modern safety science methodologies.
  • Develop long-term organizational strategies supporting portfolio expansion, novel therapeutic platforms, medical devices, biologics, xenotransplantation, digital health technologies, and future product innovations.
  • Influence organizational structure, capability development, and resource planning to support continued business growth.
  • Participate in medical conferences and present safety posters, white papers, and other safety publications.
  • Perform other duties as assigned.
Desired Qualifications
  • MD with a pulmonology specialty, U.S. practice experience, and board certification is preferred.
  • At least 3 years of clinical or medical practice experience within the United States and/or full registration with a medical licensing body is preferred.
  • State medical licensure is preferred.

About the company

U

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Silver Spring, Maryland

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted ralinepag NDA August 2026 and nebulized Tyvaso sNDA September 2026.
  • Q2 2026 net income rose to $333 million; buybacks retired 5.84% shares.
  • Phase 3 ADVANCE OUTCOMES and TETON showed improvement across PAH and IPF programs.

What critics are saying

  • Q2 2026 revenue fell 2%; Tyvaso sales dropped, exposing heavy product concentration.
  • Liquidia’s appeals and labeling fights can still blunt Treprostinil economics by 2027.
  • If ralinepag and IPF filings disappoint FDA, United Therapeutics remains a single-portfolio biotech.

What makes United Therapeutics Corporation unique

  • Martine Rothblatt built United Therapeutics around PAH drugs plus xenotransplantation, with three operating organ sites.
  • September 2026 Delaware ruling strengthened its treprostinil patent moat against Liquidia’s Yutrepia.
  • Stewartville’s August 12, 2026 DPF facility expands gene-edited pig organ production capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Holidays
  • Paid Vacation
  • Parental Leave

Company News

Associated Press
Oct 20th, 2026
United Therapeutics opens third pathogen-free xenograft facility in Houston to scale organ production

United Therapeutics has opened its third Designated Pathogen-Free (DPF) facility, in Houston, Texas. The site produces xenografts, which are animal organs for transplant into humans. The first facility opened in Christiansburg, Virginia, in 2024 to supply clinical trials. The second opened in Stewartville, Minnesota, on August 12, 2026. The Houston and Stewartville sites are built to scale commercial production if regulators approve the products. The facilities use air and water filtration, filtered feed, and decontamination entryways to keep out pathogens. Solar arrays offset a significant part of their energy use. "Every day, people with end-stage organ disease die waiting for an organ that never comes," said chief executive officer Martine Rothblatt. The products remain investigational and are not approved anywhere.

The Business Journals
Oct 20th, 2026
United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth.

United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth. Oct 20, 2026 Preview this article 1 min United Therapeutics has been working toward a Houston presence for over a year, and its newly opened facility will soon call pharma giants Eli Lilly and Bristol Myers Squibb its neighbors. Don't Stop Here - Continue Reading For $1 Per Week Secure 4 weeks of award-winning news and trusted insights Subscribe for only $4

Yahoo Finance
Oct 16th, 2026
Two cash-rich stocks to watch, United Therapeutics and Core Natural Resources, and one to avoid

StockStory has named two cash-generating stocks to watch and one to avoid, arguing that strong cash flow alone does not guarantee good returns. It passes on Simply Good Foods, the maker of Atkins products. Revenue grew 5.2% annually over three years, sales are estimated to fall 9.9% in the next 12 months, and operating margin dropped 31.9 percentage points. The stock trades at $11.12, or 6.5x forward earnings. United Therapeutics, with a free cash flow margin of 34.6%, grew revenue 14.7% a year over five years and posts a 29.1% return on capital. It trades at $541.55, or 18.3x forward earnings. Core Natural Resources, a coal miner with a 6.1% free cash flow margin, grew revenue 15.6% annually over ten years to $4.27 billion. Its shares cost $89.05, or 20.7x forward earnings.

STAT
Oct 14th, 2026
FDA adcomm members' ties to industry under scrutiny.

FDA adcomm members' ties to industry under scrutiny. The FTC going after Martin Shkreli again, a study on GLP-1s and social outcomes, and more biotech news. Oct. 14, 2026 National Biotech Reporter Good morning. Yesterday, we got the devastating news that STAT's infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time to read this tribute to her. The need-to-know this morning. * Liquidia and United Therapeutics reached a settlement agreement that resolves their ongoing patent litigation over Liquidia's treatment for pulmonary arterial hypertension. New trial to test effect of GLP-1s on social outcomes. Researchers in Pittsburgh are launching a novel type of GLP-1 trial - testing not only if the drug will help people with addiction, but also if it will help reduce recidivism while improving other employment, health, and housing outcomes. The Center for Addiction Science, Policy and Research (CASPR), a non-profit organizing the effort, and the Allegheny County Department of Human Services are planning to launch the trial in early 2027. They will enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both, who are also at high risk of criminal-justice involvement. Half will be randomly assigned to take Novo Nordisk's Wegovy, according to a press release issued yesterday. Your morning rundown of the science, politics, and money driving biotech today

Associated Press
Oct 13th, 2026
Liquidia to pay $380.7M to end all six lawsuits with United Therapeutics

Liquidia has settled all six lawsuits with United Therapeutics, ensuring patients with pulmonary arterial hypertension can keep using its inhaled drug YUTREPIA. The company will pay a net $380.7 million across 2026 and 2027. The deal follows a September 30, 2026, US District Court ruling that Liquidia infringed a United Therapeutics patent covering treatment of a related lung condition. Liquidia will not appeal and has asked to remove that indication from YUTREPIA's label. Payments include $175 million within 30 business days and $145.4 million in two instalments of $72.7 million, due by January 31, 2027, and April 30, 2027. Liquidia will also pay $60.3 million this month to parties with interests in related antitrust litigation. Liquidia reported preliminary third-quarter YUTREPIA net sales of $222.7 million and $396.1 million in cash as of September 30, 2026. It expects to fund the payments without new financing.